Atlas Trials

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Clinical trial NCT04159415 · COMPLETED

Trial details

NCT number
NCT04159415
Sponsor
Regeneron Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Generalized Lipodystrophy
Start date
2020-01-07
Primary completion
2022-01-05
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.